Pardes Biosciences, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Pardes Biosciences, Inc. - overview
Established
2020
Location
Carlsbad, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2020, Pardes Biosciences, Inc. operates as a biotechnology company that develops novel drugs to treat patients with Covid-19 and other viruses. In January 2021, Pardes Biosciences, Inc. raised USD 51.
61 million in Venture funding from the investors Foresite Capital, GMF Capital Partners, and Khosla Ventures. In June 2021, FS Development Corp. II, a special purpose acquisition company (SPAC) agreed to acquire Pardes Biosciences, Inc. , resulting in a merger between the two companies.
The transaction was valued at USD 75 million. The company's lead product candidate is PBI-0451, an investigational coronaviral protease inhibitor. PBI-0451 has shown activity against multiple coronaviruses in pre-clinical trials. The product is currently being tested and evaluated in Phase I clinical trial in New Zealand.
The company plans to use its funding to further develop its product candidate, PBI-0451, and to advance additional early discovery programs for its platform.
Current Investors
Khosla Ventures, GMF Capital Partners, Foresite Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.pardesbio.com
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Pardes Biosciences, Inc. - financials
| Fiscal Year Ended | Dec 31, 2021 | Dec 31, 2022 |
|---|---|---|
| Revenue (USD) | - | - |
| % Revenue Growth (YoY) | - | - |
| EBITDA (USD) | - | - |
| Operating Income (USD) | - | - |
| Operating Margin | - | - |
| % EBITDA Margin | - | - |
| NET Income (USD) | - | - |
| % Net Margin | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.